» Articles » PMID: 36276076

Hepatic Macrophage Mediated Immune Response in Liver Steatosis Driven Carcinogenesis

Abstract

Obesity confers an independent risk for carcinogenesis. Classically viewed as a genetic disease, owing to the discovery of tumor suppressors and oncogenes, genetic events alone are not sufficient to explain the progression and development of cancers. Tumor development is often associated with metabolic and immunological changes. In particular, obesity is found to significantly increase the mortality rate of liver cancer. As its role is not defined, a fundamental question is whether and how metabolic changes drive the development of cancer. In this review, we will dissect the current literature demonstrating that liver lipid dysfunction is a critical component driving the progression of cancer. We will discuss the involvement of inflammation in lipid dysfunction driven liver cancer development with a focus on the involvement of liver macrophages. We will first discuss the association of steatosis with liver cancer. This will be followed with a literature summary demonstrating the importance of inflammation and particularly macrophages in the progression of liver steatosis and highlighting the evidence that macrophages and macrophage produced inflammatory mediators are critical for liver cancer development. We will then discuss the specific inflammatory mediators and their roles in steatosis driven liver cancer development. Finally, we will summarize the molecular pattern (PAMP and DAMP) as well as lipid particle signals that are involved in the activation, infiltration and reprogramming of liver macrophages. We will also discuss some of the therapies that may interfere with lipid metabolism and also affect liver cancer development.

Citing Articles

Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism.

Jang J, Sung J, Huh J Immune Netw. 2025; 25(1):e12.

PMID: 40078789 PMC: 11896663. DOI: 10.4110/in.2025.25.e12.


Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development.

Alba M, Ebright B, Hua B, Slarve I, Zhou Y, Jia Y Front Physiol. 2023; 14:1098467.

PMID: 36818443 PMC: 9932286. DOI: 10.3389/fphys.2023.1098467.

References
1.
Rivera K, Quinones V, Amigo L, Santander N, Salas-Perez F, Xavier A . Lipoprotein receptor SR-B1 deficiency enhances adipose tissue inflammation and reduces susceptibility to hepatic steatosis during diet-induced obesity in mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(6):158909. DOI: 10.1016/j.bbalip.2021.158909. View

2.
Liu L, Zhang Z, Zheng B, Shi Y, Duan M, Ma L . CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology. 2018; 69(1):143-159. DOI: 10.1002/hep.30134. View

3.
Bi H, Zhang Y, Wang S, Fang W, He W, Yin L . Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer. Oncol Lett. 2019; 18(4):4176-4184. PMC: 6732969. DOI: 10.3892/ol.2019.10735. View

4.
Zhang X, Tan X, Zeng G, Misse A, Singh S, Kim Y . Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology. 2010; 52(3):954-65. PMC: 3100799. DOI: 10.1002/hep.23747. View

5.
Tacke F, Zimmermann H, Trautwein C, Schnabl B . CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol. 2011; 26(3):523-9. PMC: 3058722. DOI: 10.1111/j.1440-1746.2010.06436.x. View